Klifeck GmbH
- Address
- lock Available on a paid plan
Respiratory Tract Diseases
Klifeck GmbH conducts focused research on asthma and related airway disorders. One study tests a high‑dose fluticasone propionate inhaler against standard rescue therapy. Another program investigates the oral agent dexpramipexole for preventing severe asthma attacks. Add‑on inhaled therapies such as CHF6001 are examined as complements to triple maintenance treatment for chronic obstructive pulmonary disease. A comparative device study assesses the equivalence of CHF5993 metered‑dose inhalers in mild to moderate asthma.
- Evaluation of high‑dose inhaled corticosteroid/bronchodilator rescue inhaler
- Oral therapy aimed at reducing severe asthma exacerbations
- Inhaled anti‑inflammatory agent added to COPD triple therapy
- Device equivalence testing of metered‑dose inhalers for asthma control
- Investigation of dual‑dose regimens to improve lung function
The Delitzsch‑based site has launched six clinical trials with five investigators. As a commercial pharmaceutical company, Klifeck GmbH leverages its expertise to advance respiratory therapeutics.
Virus Diseases
Research at Klifeck GmbH also targets Cytomegalovirus infection. A novel mRNA vaccine, mRNA‑1647, is being tested to prevent primary CMV infection in seronegative adults. Safety and reactogenicity of the three‑dose regimen are evaluated alongside immunogenicity outcomes. The program aims to provide a preventative option for a virus that can cause serious disease in immunocompromised individuals.
- Development of an mRNA vaccine for CMV prophylaxis
- Assessment of immunogenic response after a three‑dose schedule
- Monitoring of safety and reactogenicity in healthy volunteers
- Evaluation of vaccine efficacy in seronegative participants
- Exploration of novel antiviral prevention strategies
Six trials across respiratory and viral indications are currently active at the Bitterfelder Strasse facility. The site’s multidisciplinary team of five investigators supports both therapeutic areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Chiesi Farmaceutici S.p.A.2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Chiesi Farmaceutici S.p.A.5trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klifeck GmbH
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Formoterol Fumarate Dihydrate | 3 | Unknown | 2024-04-10 | 2026-04-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.